- By Shreyansh Mangla
- Mon, 21 Jul 2025 02:56 PM (IST)
- Source:JND
Anthem Biosciences IPO Listing: Anthem Biosciences made a strong entry into the stock market today, with its shares opening at Rs 723.05 per share, a significant 26.85% increase from its IPO price of Rs 570. This robust debut confirmed expert predictions, offering substantial immediate profits to investors and reflecting strong confidence in the biopharmaceutical company's prospects.
The company's stock started trading at Rs 723.10, surging 26.85 per cent from the issue price on the BSE. Later, it jumped 31 per cent to Rs 746.70. At the NSE, the stock was listed at Rs 723.05, rallying 26.85 per cent. The company's market valuation stood at Rs 40,716.73 crore.
ALSO READ: New Income Tax Bill: Select Committee Report On New I-T Bill Presented In Lok Sabha
The Rs 3,395-crore initial public offer of Anthem Biosciences Ltd got subscribed 63.86 times on the closing day of bidding on Wednesday last week, driven by overwhelming participation from institutional buyers. The initial share sale had a price band of 540-570 per share. Since the IPO was entirely an Offer For Sale (OFS), the company will not receive any funds from the issue, and the proceeds will go to the selling shareholders.
The company, which specialises in the research, development and production of diet supplements, specialised fermentation-based Active Pharmaceutical Ingredients (APIs) including probiotics, enzymes, peptides, nutritional actives, vitamin analogues and biosimilars and generic drugs, covers the entire process from raw material sourcing to final product manufacturing.
ALSO READ: Stock Market Updates Today: Sensex, Nifty Rise In Morning Trade; Mahindra, Wipro, SBI Shares Rally
Its comprehensive services for all stages of drug development, coupled with its focus on research-driven innovation, position it well in the market. Sustaining this high stock value will depend on Anthem's ability to retain customers in a competitive and regulated market, as well as its capacity for expanding growth plans and advanced facilities.
Anthem's entry is expected to bring a fresh perspective to global biotechnology trends and contribute to India's pharmaceutical manufacturing goals. The company's strong fundamentals, including predicted healthy profit margins and global growth prospects, make it an attractive option for investors.
